NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
Loading market information…
NSE · SAGILITY.NS · INR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Sagility India Limited’s quoted price sits in the lower half of its reported 52-week range, 22.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sagility India Limited’s forward annual dividend is ₹0.30 per share, paid semi-annual. The forward yield is 0.67% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Sagility India Limited’s next earnings report is currently expected on Nov 30, 2026, with estimated earnings per share of ₹0.59. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sagility India Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Bengaluru, India, and established in 2021, Sagility India Limited specializes in providing comprehensive business process management (BPM) services. The company primarily caters to clients within the healthcare and insurance industries across multiple international markets, including India, Jamaica, the Philippines, the United States, and Colombia. Its extensive range of services encompasses claims management and cost containment, member engagement and enrollment, benefits plan construction, and ensuring payment integrity and accurate billing. Additionally, Sagility offers credentialing, clinical and case management, provider solutions, robust analytics, front and back-office support, and data management. The company further delivers utilization and care management, population health management, and a full spectrum of revenue cycle management functions, such as financial clearance, medical coding, billing, and accounts receivable follow-up. Sagility India Limited operates as a subsidiary of Sagility B.V.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | May 14, 2025 | ₹0.51+14.77% vs estimate | ₹15.69B+0.68% vs estimate |
|---|
| Q3 2025 | Feb 5, 2025 | ₹0.58 | ₹14.53B |
|---|
| Q2 2025 | Nov 25, 2024 | ₹0.33 | ₹13.25B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,761.00+₹3.50 (+0.2%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
₹9,664.00+₹105.50 (+1.1%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.78% below the high.
₹4,580.00+₹23.00 (+0.5%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.76% below the high.
₹2,244.00+₹62.10 (+2.85%)
Laurus Labs Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
₹681.75-₹7.95 (-1.15%)
Lenskart Solutions Limited’s quoted price sits in the upper half of its reported 52-week range, 5.97% below the high.
₹1,184.40+₹8.90 (+0.76%)
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 3.87% below the high.
₹1,710.90+₹18.10 (+1.07%)
Inventurus Knowledge Solutions Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.15% below the high.
₹306.45-₹1.50 (-0.49%)
Firstsource Solutions Limited’s quoted price sits in the upper half of its reported 52-week range, 17.57% below the high.
